AITRICS said Thursday it has won approval from the Ministry of Food and Drug Safety for its AITRICS-VC, or Vital Care, AI software that helps diagnose by predicting the aggravation of patients’ conditions.

Vital Care is an AI monitoring system that predicts the deaths of patients at intensive care units (ICU) and general wards within six hours, unexpected patient transfers to ICUs and their heart arrests, and the risk of sepsis within four hours, based on six biological signals, 11 hematological tests, and other patient information.

Vital Care has proved its performance for the first time in Korea and received approval by predicting sepsis, death, unexpected transfers to ICUs, and the possibility of deaths at ICUs.

There have been high unmet demands for monitoring technology to help medical workers prepare for emergencies in general wards and ICUs by predicting risk factors before bad situations occur to patients. Vital Care reportedly has shown could predict the deterioration of patient conditions in ICUs and general wards while recording accurate prediction scores for each indication.

“Vital Care is the first innovative medical device in Korea to be used in general wards and intensive care units. In addition, it is AITRICS'” first medical device designed to ensure the clinical value needed in the medical field and to prioritize usability,” said Ahn Byeong-eun, in overall charge of medical AI at the company.

AITRICS is securing explainable AI (XAI) that can explain itself through external verification with the Cleveland Clinic. In addition, some of Vital Care’s functions are being reviewed by the U.S. Food and Drug Administration for approval.

“We will continue to join the patient's treatment journey through advanced medical services and strengthen our position in the field of medical artificial intelligence through solid research and development,” Ahn said.